Genmab — November 2019
-
The FDA announces a forthcoming public
advisory committee meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee December 13 : The committee will discuss...
teprotumumab solution for intravenous use, submitted by Horizon Pharmaproposed for the treatment of active thyroid eye disease
-
Ved kurs 2150 siger jeg nok: Tak for pengene!
-
Done
Det burde være latest and greatest https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/79379_darzalex_20Nov2019.png -
-
Janssen to test NKTR-255 in preclinical research studies
with therapies in Janssen’s oncology portfolio
■ Janssen responsible for the costs of the preclinical
studies
■ Nektar will contribute NKTR-255 for the studies and
cover the supply cost of its drug candidate
■ Nektar and Janssen will each maintain global
commercial rights to their respective drug candidates -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind